Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter E Westerweel

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Blood Advances|December 23, 2021
COVID-19 vaccination in patients with immune thrombocytopeniaChantal Visser, Maurice Swinkels, Erik D van Werkhoven, et al.
Blood Neoplasia|April 20, 2026
Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaNiels Westra, Elena Ropero Cerro, Edwin Schilder, et al.
European Journal of Clinical Nutrition|August 10, 2024
Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
American Journal of Hematology|March 16, 2026
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin LymphomaWouter Verhaar, Flores Weverling, Jahanzaib Khwaja, et al.
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Haematologica|September 8, 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient populationCamille C B Kockerols, Jeroen J W M Janssen, Nicole M A Blijlevens, et al.
Research and Practice in Thrombosis and Haemostasis|February 4, 2021
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA studyEva N Hamulyák, Hanke M G Wiegers, Luuk J J Scheres, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Blood Advances|December 23, 2021
COVID-19 vaccination in patients with immune thrombocytopeniaChantal Visser, Maurice Swinkels, Erik D van Werkhoven, et al.
Blood Neoplasia|April 20, 2026
Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemiaNiels Westra, Elena Ropero Cerro, Edwin Schilder, et al.
European Journal of Clinical Nutrition|August 10, 2024
Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
American Journal of Hematology|March 16, 2026
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin LymphomaWouter Verhaar, Flores Weverling, Jahanzaib Khwaja, et al.
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.
American Journal of Hematology|May 21, 2024
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysisCamille Kockerols, Peter J M Valk, Stéphanie Dulucq, et al.
Haematologica|September 8, 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient populationCamille C B Kockerols, Jeroen J W M Janssen, Nicole M A Blijlevens, et al.
Research and Practice in Thrombosis and Haemostasis|February 4, 2021
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA studyEva N Hamulyák, Hanke M G Wiegers, Luuk J J Scheres, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Pageof 11